Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | GRN | P28799 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419910 | 0.84 | GRN (0.63) | MAPTTAS1R3TAS1R1CYP1A2CYP2C19 | |
| SCHEMBL16600514 | 0.81 | CHRNA1 (0.55) | MAPTALDH1A1TAS1R3TAS1R1CYP1A2 | |
| SCHEMBL26785504 | 0.80 | MAPT (0.53) | MAPTALDH1A1TAS1R3TAS1R1CYP1A2 | |
| SCHEMBL531992 | 0.80 | SMN1; SMN2 (0.57) | MAPTTAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL14331842 | 0.80 | MLYCD (0.50) | MAPTALDH1A1TAS1R3TAS1R1CYP1A2 | |
| SCHEMBL20791763 | 0.79 | TAS1R3 (0.47) | ALDH1A1TAS1R3TAS1R1CYP1A2CYP2C19 | |
| SCHEMBL22490279 | 0.78 | RAB9A (0.56) | MAPTALDH1A1TAS1R3TAS1R1CYP1A2 | |
| SCHEMBL27405373 | 0.78 | TAS1R3 (0.55) | TAS1R3TAS1R1CYP1A2CYP2C19GRN | |
| Hydrochloric Acid SCHEMBL9639558 | 0.78 | TAS1R3 (0.71) | MAPTALDH1A1TAS1R3TAS1R1CYP1A2 | |
| SCHEMBL1460210 | 0.77 | ALDH1A1 (0.54) | MAPTALDH1A1CYP1A2CYP2C19ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181077-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2020-06-11 | — | — | US | disclosed |
| US-20170158633-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2017-06-08 | — | — | US | disclosed |
| US-9527835-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2016-12-27 | — | — | US | disclosed |
| WO-2015123437-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225375-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225375-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 1937/4885ALDH1A1 457/4885TAS1R3 4798/4885 |
| US-20200181077-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 1937/4885ALDH1A1 457/4885TAS1R3 4798/4885 |
| US-20170158633-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 1937/4885ALDH1A1 457/4885TAS1R3 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.